Association of the British Pharmaceutical Industry

#CPC25 discussions about industrial strategy.

Lord Willet's Chair of the Resolution Foundation and Chair of the Regulatory Innovation Office has recognised how important regulation is to growth and investors.

Read our report on Regulation: www.abpi.org.uk/publications...

Great session with @astra-zeneca.bsky.social UK today at #CPC25 on the potential of life sciences.

For Shadow Health Minister Dr Caroline Johnson, important recognition that we need to get new medicines to patients quicker.

📦 From research labs to your pharmacy…

🛣️ Our supply chain video explains how medicines make their journey through the supply chain to reach patients.

Watch the full video⬇️

www.abpi.org.uk/value-and-ac...

Delivering the vaccination strategy Information and resources for healthcare leaders on the barriers, success factors and enablers for vaccination programme delivery.

🚨NEW: @nhsconfed.org has published a new resource hub on vaccination, to help the NHS make sure that everyone who could benefit from vaccination takes it up.

We were happy to help support the publication. www.nhsconfed.org/vaccination-... #VaccinesSaveLives

Charity-Industry Partnership Case Study Library

🚨New resource on the ABPI website: Check out our library of industry-charity partnership case studies.

Partnerships help improve outcomes for patients, address healthcare challenges, and drive innovation.

Visit our library: bit.ly/3IFQtO3 @pifonline.bsky.social

For Health Minister @ashleydaltonmp.bsky.social, vaccination sits across all three shifts in the #NHS10YearPlan.

"We need to be in communities, that's why the neighbourhood health service will be so important."

#LabourConference2025 @ippr.org @age-uk.bsky.social

At #Lab25, our President Russell Abberley is discussing the future of UK vaccination policy with @ashleydaltonmp.bsky.social, Darius Hughes of Moderna,
Caroline Abrahams of @age-uk.bsky.social & Sebastian Rees of @ippr.org

At #Lab25 we have been discussing innovation, life sciences & the #NHS10YearPlan, hosted by
@labourtogether.bsky.social

@steveyemm-mp.bsky.social highlighted challenges being faced by industry, and said it is vital that government addresses those to deliver for patients.

Making Wales a destination for industry clinical trials and medical research Clinical trials are at the heart of developing new medicines and vaccines. They offer the opportunity for patients to receive early access to potentially lifesaving treatments and deliver huge benefit...

In the lead up to the next Senedd election, we are calling on Members of the Senedd to champion and support long-term investment in clinical research, embedding research in the NHS, as business as usual.

Read our latest blog: www.abpi.org.uk/media/blogs/...

ICYMI: @torbett.bsky.social spoke to BBC Business earlier about investment in medicines.

The UK spends just 9% of the NHS budget on medicines. For most of Europe it's 14% - 20%.

This gap leaves the UK at risk of missing out on investment.

We believe it is possible to find a solution. 👇

A recent ABPI report explores how the UK can attract significant inward investment, provided it can maintain these advantages amid growing competition.

Take a look: www.abpi.org.uk/publications...

🧵The UK is fortunate to have an excellent science base which continues to offer world-class scientific expertise and globally respected academic institutions.

It is also one of the world’s most vibrant environments for biotech and spinout companies. (1/2)

ABPI launches manifesto to make Scotland a leader in R&D and cutting-edge medicines The ABPI has launched its manifesto for the next Scottish Government, calling for urgent action to unlock Scotland’s full potential as a partner of choice for life sciences and health innovation.

🚨Out today: our manifesto to unlock Scotland’s full potential in life sciences & innovation. 🧬

@torbett.bsky.social: With the right policy choices, Scotland can become a powerhouse for discovery, development & delivery of medicines, vaccines & diagnostics.

More: bit.ly/4gnzFHS

This is an important publication that outlines the current status of NAMs, as well as the challenges and opportunities associated with their adoption.

We were pleased to feed into this report, alongside @nc3rs.bsky.social and @mhragovuk.bsky.social.

Read more below. ⬇️

Today - 11/09/2025 - BBC Sounds News and current affairs, including Sports Desk, Weather and Thought for the Day.

ICYMI: Our Chief Exec @torbett.bsky.social was on
the Today programme this morning, discussing the sad news that life sciences investment is being withdrawn from the UK.

Listen again here from about 16 mins and 45 seconds in: www.bbc.co.uk/sounds/play/...

Our latest report, ‘Creating the conditions for investment and growth’ sets out a new framework to assess the UK’s competitiveness and identify the actions required to make it a top destination for global pharmaceutical investment. (3/3)🧵

Find out more: www.abpi.org.uk/publications...

But while investment in the UK has grown in recent years, we’re lagging behind our global peers. Other countries are making bold moves to attract more life sciences investment – and the UK risks falling behind unless action is taken. (2/3)🧵

The pharmaceutical industry invests more in R&D than any other sector – driving the discovery of new medicines and vaccines that improve health outcomes for patients and strengthen the UK economy. (1/3)🧵

Tough talk from Streeting – but he still needs a deal with big pharma Health secretary calls industry ‘shortsighted’ but there is danger in giving UK better terms than much of rich Europe

Today's Guardian explains why a deal with our industry on medicines is needed.

"In theory, the current voluntary agreement can run unaltered all the way to 2028, but if that were to happen it would be a disaster for the government’s life sciences strategy."

www.theguardian.com/business/nil...

Our Chief Exec @torbett.bsky.social spoke to Times Radio about medicine rebates.

The government's offer would still mean the industry paying £13 billion back to government over 3 years - 3 times more than any other European country.

We could not accept that, but hope to continue discussions.

Accelerated review of VPAG concludes without agreement The ABPI can confirm that industry and government have been unable to reach an agreement on changes to a controversial medicines payment scheme which is undermining UK patient access to innovative med...

The accelerated review of the VPAG scheme has concluded without agreement, but the issues it was set up to resolve continue to demand urgent action.

We want to continue constructive dialogue with government to find a solution.

Our statement here: www.abpi.org.uk/media/news/2...

Rydym yn falch o fod yn bartner digwyddiad i WelshConfed25

📆 Dydd lau 6 Tachwedd
📍 Stadiwm Dinas Caerdydd

Ymunwch â ni i gysylltu, cydweithio, rhannu mewnwelediadau a datblygu datrysiadau arloesol i ddarparu gofal o ansawdd uchel i bawb

www.nhsconfed.org/WelshConfed25
@welshnhsconfed.bsky.social

We’re proud to be an event partner for WelshConfed25.
Registration for WelshConfed25 is now open!

📆 Thursday 6 November
📍Cardiff City Stadium

Join us to connect, collaborate, share insights and develop innovative solutions to deliver high quality care for all.

www.nhsconfed.org/WelshConfed25

Earlier this week DHSC published a policy paper on managing robust and resilient supply chains for medicines.

We support the government’s activities to improve shortage management and strengthen medicines supply chain resilience.

Read the paper here: www.gov.uk/government/p...

Did you know: We have guidance to help the NHS and industry work together effectively.

Doing so can benefits patients and the NHS alike.

Find out more: www.abpi.org.uk/publications...

We are pleased to retain our #PIFTick certification for another year! @pifonline.bsky.social

Our latest report features a national survey of NHS professionals involved in the delivery of homecare.

The results are clear:
🏠92% say homecare increases NHS capacity.
💷90% say it delivers cost savings.
🧑🏿‍🤝‍🧑🏿71% say it improves access for patients.

Read more: www.abpi.org.uk/publications...

👩‍⚕️Without pharmaceutical investment, access to homecare could shrink. Nearly half (49%) of NHS professionals say fewer patients would receive homecare if it were solely NHS-funded. (4/4)

🛏️New analysis from Kent and Medway NHS & Social Care Partnership Trust shows patients on homecare spent 2.4 fewer days in hospital on average and had half the number of A&E visits compared to those treated in hospital. (3/4)

💊Each year, the pharmaceutical industry invests £173 million to fund clinical homecare for more than 512,000 patients - supporting access to life - changing treatments outside hospital settings. (2/4)